We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides

By LabMedica International staff writers
Posted on 23 Apr 2026

Pathologists are essential for cancer diagnosis and treatment planning, yet a global workforce shortage is straining services. More...

Nearly 20 million new cases are diagnosed each year, and traditional artificial intelligence (AI) tools require massive datasets and repeated retraining for each tumor type. These hurdles slow deployment, particularly across diverse clinical settings. Researchers now introduce a plug-and-play pathology system that classifies multiple cancers from only a few annotated slides.

At The Hong Kong University of Science and Technology (HKUST), investigators developed PRET (Pan-cancer Recognition without Example Training), a pathology analysis system designed to recognize multiple tumor types from minimal samples without additional training. Positioned as a plug-and-play tool for digital pathology, PRET targets routine diagnostic tasks that can burden laboratory workflows.

The system applies “in-context learning,” a strategy adapted from natural language processing, to whole-slide image analysis. During inference, PRET adapts to new cancer types and tasks by referencing just one to eight annotated tumor slides, rather than relying on task-specific fine-tuning. The approach is described as supporting cancer screening, tumor subtyping, tumor segmentation, and lymph node metastasis detection.

Validation drew on 23 international benchmark datasets from institutions in the Chinese Mainland, the United States, and the Netherlands, encompassing 18 cancer types and multiple diagnostic tasks. PRET demonstrated stable, robust generalizability across different populations and regions with varying medical resources. The evaluation addressed clinically relevant endpoints across settings.

Across these datasets, the system outperformed existing methods in 20 tasks. Its area under the curve (AUC), a measure of diagnostic accuracy, exceeded 97% in 15 tasks; results included an AUC of 100% in colorectal cancer screening and 99.54% in esophageal squamous cell carcinoma tumor segmentation. For lymph node metastasis detection, PRET achieved an AUC of approximately 98.71% using only eight slide samples, surpassing the average performance of 11 pathologists, whose AUC averaged approximately 81%.

The study is published in Nature Cancer. Collaborating institutions included Guangdong Provincial People’s Hospital and Harvard Medical School. The team plans to further enhance performance and extend applications to genetic mutation prediction and patient prognosis assessment.

“The core value of the PRET system lies in breaking down the traditional barriers of ‘massive data and repetitive training,’ enabling AI-powered pathology systems to be applied in real clinical settings at lower cost and with greater flexibility. This not only helps alleviate the workload pressure faced by pathologists, but also has the potential to improve access to cancer diagnosis in underserved regions,” said Prof. Li Xiaomeng, Assistant Professor of the Department of Electronic and Computer Engineering and Associate Director of the Center for Medical Imaging and Analysis, The Hong Kong University of Science and Technology.

“Through this ‘plug-and-play’ system, we hope that advanced and precise AI-powered diagnostic services can transcend geographical and resource constraints, thereby promoting global health care equity,” said Prof. Li Xiaomeng.

Related Links
HKUST


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Blood Protein Analysis Reveals Menopause-Associated Signals of Brain Aging

Menopause affects women across midlife and is often accompanied by endocrine changes, hot flashes, brain fog and sleep disturbances. Women spend roughly one third of their lives after the menopause transition,... Read more

Molecular Diagnostics

view channel
Image:(L to R) Co-first author Yuan Feng, PhD, corresponding author Xiaotu Ma, PhD, and co-first author Hanxia Li, PhD, all of the St. Jude Department of Computational Biology. (Photo courtesy of St. Jude Children\'s Research Hospital)

Genomic Profiling Predicts Relapse Risk by Subtype in Pediatric Leukemia

B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with more than 90% of patients surviving with modern treatments. Outcomes are worse when the disease returns, however, making... Read more

Hematology

view channel
Image: The newly certified products are the CytoCell ATM Deletion FISH Probe, CytoCell IGH Plus Breakapart FISH Probe, CytoCell IGH/FGFR3 Plus Translocation, Dual Fusion FISH Probe, and CytoCell IGH/MYEOV Plus Translocation, Dual Fusion FISH Probe. (Photo courtesy of OGT)

Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers

Hematological malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphoid leukemia, and multiple myeloma require assessment of key cytogenetic abnormalities.... Read more

Immunology

view channel
Image: Study design and collection of lower respiratory tract lining fluid (RTLF) using the PExA instrument. (Aguilera K, Hober A, Greilert Norin N, et al. eBioMedicine, 2026. doi:10.1016/j.ebiom.2026.106538)

Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways

Respiratory viruses such as influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) require immune protection across the airway mucosa. Antibodies in the respiratory tract lining are important... Read more

Microbiology

view channel
Image: Four-quadrant streaking of fecal samples on chromogenic UTI agar shows various patterns of relative bacterial species abundance. The assorted shapes of the pinkish colonies indicate different E. coli strains. (Photo courtesy of Sokurenko Lab)

Stool Testing Predicts UTI Risk and Guides Antibiotic Selection

Urinary tract infections (UTIs) are a common reason for antibiotic prescribing in general medical practice and can be painful in postmenopausal women, sometimes progressing to kidney infection or life-threatening... Read more

Industry

view channel
Image: Onvaro’s commercial portfolio will be anchored by the binx io platform, an FDA-cleared, CLIA-waived molecular point-of-care system with more than 1,000 installed instruments. (Photo courtesy of binx health)

New Diagnostics Company Onvaro Formed to Expand Decentralized Testing

Sapphiros, a diagnostics platform backed by investment funds managed by KKR, and binx health, a point-of-care diagnostics company backed by Hildred, have combined to form Onvaro. The new diagnostics company... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.